Asunto(s)
Enfermedad de la Arteria Coronaria/epidemiología , Lipoproteína(a)/sangre , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Humanos , Radiografía , Factores de Riesgo , Triglicéridos/sangreRESUMEN
This randomized prospective clinical study evaluated the lipid-lowering effects and safety of a new combination regimen in patients with mixed hyperlipidemia. The data show that alternate-day simvastatin and fenofibrate therapy was as effective as the standard daily combination of the same drugs at the same doses, and it was safer, less expensive, and more tolerable.
Asunto(s)
Fenofibrato/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Hiperlipoproteinemia Tipo V/tratamiento farmacológico , Hipolipemiantes/administración & dosificación , Simvastatina/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Femenino , Fenofibrato/efectos adversos , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Hiperlipoproteinemia Tipo V/sangre , Hipolipemiantes/efectos adversos , Lípidos/sangre , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Simvastatina/efectos adversosRESUMEN
We investigated whether pre- and posttreatment analysis of erythrocyte membrane Na+,K(+)-ATPase (EC 3.6.1.37) activity would be a useful marker for screening hypertensive patients to determine who might benefit from treatment with calcium antagonists. Erythrocyte Na+,K(+)-ATPase activity and sodium and potassium (ENa, EK) contents were determined in controls and in patients with untreated essential hypertension before and after 4 weeks of treatment with nitrendipine. Na+,K(+)-ATPase activity was significantly (P < 0.0001) less in untreated hypertensive patients (n = 15; 104.60 +/- 29.37 nmol of phosphate produced per milligram of protein per hour) than in controls (n = 15, 171.87 +/- 34.42). After 4 weeks of nitrendipine treatment Na+,K(+)-ATPase activity was greater than in the pretreatment group: 158.13 +/- 26.80 (P < 0.001). Pretreatment ENa contents (22.34 +/- 4.77 mmol/L) were significantly (P < 0.0001) higher than in the normotensive group (13.14 +/- 3.32 mmol/L), but there was no significant difference between the controls and the posttreatment group (14.84 +/- 3.49 mmol/L). The control and pretreatment groups showed negative correlations between enzyme activity and systolic/diastolic blood pressure (P < 0.0001). The control and the posttreatment groups showed an inverse correlation between enzyme activity and ENa contents: r = -0.608 (P < 0.05) and r = -0.724 (P < 0.001), respectively. Although Na+,K(+)-ATPase is restored in hypertensive patients receiving nitrendipine treatment, relative changes in enzyme activity in relation to relative reduction in blood pressure response to treatment were not correlated.
Asunto(s)
Bloqueadores de los Canales de Calcio/uso terapéutico , Eritrocitos/enzimología , Hipertensión/tratamiento farmacológico , ATPasa Intercambiadora de Sodio-Potasio/sangre , Adulto , Anciano , Femenino , Humanos , Hipertensión/enzimología , Masculino , Persona de Mediana Edad , Nitrendipino/uso terapéutico , Potasio/sangre , Valores de Referencia , Sodio/sangreRESUMEN
The purpose of the study was to investigate the antihypertensive effect and the dependability of labetalol in 21 essential hypertensive patients. After a period of one week without drugs, the patients were first given placebo for one week and subsequently 200 mg or 400 mg labetalol daily for eight weeks. Lipid assays were performed and renal and hepatic functions determined before and after therapy. In conclusion, it was shown that labetalol effectively controls blood pressure and reduces heart rate without causing any changes in renal and hepatic functions and lipid metabolism.
